Corium International Inc is incorporated in Delaware in 1995 as Corium Corporation and in 1996 as Converting Systems, Inc. In 2002, these companies were merged and re-named Corium International, Inc. and its place of incorporation changed to Delaware. The Company is a commercial stage biopharmaceutical company. It develops, manufactures and commercializes specialty pharmaceutical products. The Company has developed six marketed products in the prescription drug and consumer markets, and it is the sole commercial supplier of each of those products for its marketing partners. These marketed products are Clonidine Transdermal Delivery System, or TDS, Fentanyl TDS and four Crest Advanced Seal Whitestrips products. The Company is developing two additional products utilizing its proprietary technologies that it plans to advance into Phase 2 trials in 2014 and 2015. Some of its products or product candidates contain controlled substances, the making, use, sale, importation and distribution of which are subject to regulation by state, federal and foreign law enforcement and other regulatory agencies.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.